

Consensus Outlook: Multiple Sclerosis

<https://marketpublishers.com/r/C6584297024EN.html>

Date: August 2013

Pages: 35

Price: US\$ 7,495.00 (Single User License)

ID: C6584297024EN

Abstracts

Over the next five years, the global multiple sclerosis (MS) market is set to grow from \$14.4 billion in 2012 to \$18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance

A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017

Timely event-driven market forecast report and data analysis updates over the next 12 months

Contents

1. FORECAST DATA MODEL (EXCEL)

Tabs:

- Market size
- Product sales
- Company forecast
- Mechanism of action
- Future Events

2. FORECAST ANALYSIS REPORT (PDF)

Contents:

- FirstWord Analysis Highlights
- Research Methodology
- Multiple Sclerosis Marketplace
- Key Multiple Sclerosis Developers
- Multiple Sclerosis Class Dynamics
- Tecfidera (dimethyl fumarate; Biogen) forecast
- Aubagio (teriflunomide; Sanofi) forecast
- Gilenya (fingolimod; Novartis Mitsubishi Tanabe) forecast
- Tysabri (natalizumab; Biogen) forecast
- Copaxone (glatiramer acetate; Teva) forecast
- Avonex (interferon beta-1a; Biogen) forecast
- Betaseron (interferon beta-1b; Bayer) forecast
- Rebif (interferon beta-1a; Merck Serono) forecast
- Extavia (interferon beta-1b; Novartis) forecast
- Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast
- Laquinimod (Teva/Active Biotech) forecast
- Daclizumab HYP (Biogen/AbbVie) forecast
- Ocrelizumab (Biogen/Roche/Biogen) forecast

I would like to order

Product name: Consensus Outlook: Multiple Sclerosis

Product link: <https://marketpublishers.com/r/C6584297024EN.html>

Price: US\$ 7,495.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6584297024EN.html>